ID: MRFR/Pharma/2956-HCR | 200 Pages | Author: Kinjoll Dey | March 2024
Brief TOC
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis
6. Global Macrolide Antibiotics Market, by Drug
6.1 Introduction
6.2 Azithromycin
6.3 Clarithromycin
6.4 Erythromycin
6.5 Fidaxomicin
6.6 Telithromycin
7. Global Macrolide Antibiotics Market, by Route of Administration
7.1 Introduction
7.2 Infection Due to Mycoplasma Pneumonia, Legionella Sp, or Bordetella pertussis
7.3 Symptomatic Cat-scratch Disease
7.4 Bacillary Angiomatosis
7.5 Peliosis Hepatis in Patients with AIDS
7.6 Cerebral Toxoplasmosis
7.7 Uncomplicated Skin Infections
7.8 Others
7.8.1 Babesiosis
7.8.2 Chlamydia Trachomatis Urethritis and Cervicitis
8. Global Macrolide Antibiotics Market, by End User
8.1 Introduction
8.2 Hospitals
8.3 Dermatology Clinics
8.4 Pharmaceutical Companies
8.5 Others
9. Global Macrolide Antibiotics Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Australia
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa
10 Company Landscape
10.1 Introduction
10.2 Market share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles
11.1 Merck Sharp & Dohme Corp
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Pfizer Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Teva Pharmaceutical Industries Ltd.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Fresenius Kabi USA
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Sandoz International GmbH
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Macrolide Pharmaceuticals
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Neo QuÃmica
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Healthcare Industry
13 Appendix
Macrolide Antibiotics Market Segmentation Tab
Macrolide Antibiotics Drugs Outlook (USD Billion, 2018-2032)
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Macrolide Antibiotics Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
US Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Canada Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Europe Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Germany Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
France Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
UK Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Italy Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Spain Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Rest Of Europe Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Asia-Pacific Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
China Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Japan Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
India Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Australia Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Rest of the World Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Middle East Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Africa Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others
Latin America Outlook (USD Billion, 2018-2032)
Macrolide Antibiotics by Drugs
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin
Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)
Oral
Parenteral
Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others
Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)
Hospitals
Dermatology clinics
Pharmaceutical companies
Others